$2.5 Million Funding Available to Australian Biomedical Researchers

CSL Limited today announced a revised profit outlook for
fiscal 2018.

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia

The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth

- Industry’s role in ensuring access to medicine is an imperative, not an afterthought
- Patient engagement is a key driver to strengthen access